The CDMO completed site construction and infrastructure installation at its 50,000-square-foot facility, with full-scale GMP production slated for this summer.
J&J looks to develop end-to-end automated platform for autologous CAR-T cell manufacturing, while Thermo Fisher aims for robotic production of cell and gene therapies.
The company claims it is the only CDMO with BFS capabilities for both biologics and small molecules from early phase development through to commercialization.
